<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04926233</url>
  </required_header>
  <id_info>
    <org_study_id>1237-0091</org_study_id>
    <nct_id>NCT04926233</nct_id>
  </id_info>
  <brief_title>Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study</brief_title>
  <official_title>Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the study are to use US and UK data to describe the characteristics&#xD;
      of Chronic Obstructive Pulmonary Disease (COPD) patients according to various demographic,&#xD;
      lifestyle, clinical, and medication use.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2019</start_date>
  <completion_date type="Actual">April 14, 2020</completion_date>
  <primary_completion_date type="Actual">April 14, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - US</measure>
    <time_frame>At index date of cohort entry (baseline; time of COPD diagnosis).</time_frame>
    <description>Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the United States (US) IBM MarketScan was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - UK</measure>
    <time_frame>At index date of cohort entry (baseline; time of COPD diagnosis).</time_frame>
    <description>Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the the United Kingdom (UK) CPRD GOLD database was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Charlson Comorbidity Index (CCI) at the Time of COPD Diagnosis</measure>
    <time_frame>At index date of cohort entry (baseline; time of COPD diagnosis).</time_frame>
    <description>The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Age of Patients Receiving First Maintenance Treatment - US</measure>
    <time_frame>At index date of the first maintenance treatment</time_frame>
    <description>Age of chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United States (US) IBM MarketScan database was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Charlson Comorbidity Index (CCI) of Patients Receiving First Maintenance Treatment - US</measure>
    <time_frame>At index date of the first maintenance treatment</time_frame>
    <description>The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characteristics of Patients Receiving First Maintenance Treatment - US</measure>
    <time_frame>At index date of the first maintenance treatment</time_frame>
    <description>Characteristics of patients receiving first maintenance treatment among chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United States (US) IBM MarketScan database were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Age of Patients Receiving First Maintenance Treatment - UK</measure>
    <time_frame>At index date of the first maintenance treatment</time_frame>
    <description>Age of patients receiving first maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characteristics of Patients Receiving First Maintenance Treatment - UK</measure>
    <time_frame>At index date of the first maintenance treatment</time_frame>
    <description>Characteristics of patients receiving first maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Age of Patients Receiving Second Maintenance Treatment - US</measure>
    <time_frame>At index date of the second maintenance treatment</time_frame>
    <description>Age of patients receiving second maintenance treatment from the United States (US) IBM MarketScan database was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Charlson Comorbidity Index (CCI) of Patients Receiving Second Maintenance Treatment - US</measure>
    <time_frame>At index date of the second maintenance treatment</time_frame>
    <description>The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characteristics of Patients Receiving Second Maintenance Treatment - US</measure>
    <time_frame>At index date of the second maintenance treatment</time_frame>
    <description>Characteristics of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United States (US) IBM MarketScan database were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Age of Patients Receiving Second Maintenance Treatment - UK</measure>
    <time_frame>At index date of the second maintenance treatment</time_frame>
    <description>Age of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characteristics of Patients Receiving Second Maintenance Treatment - UK</measure>
    <time_frame>At index date of the second maintenance treatment</time_frame>
    <description>Characteristics of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - US</measure>
    <time_frame>At index date of the first maintenance treatment</time_frame>
    <description>Number of participants with zero exacerbations in the year prior to the start of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy the United States (US) IBM MarketScan database was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - UK</measure>
    <time_frame>At index date of the first maintenance treatment</time_frame>
    <description>Number of participants with zero exacerbations in the year prior to the start of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - US</measure>
    <time_frame>At index date of the second maintenance treatment</time_frame>
    <description>Number of participants with zero exacerbations in the year prior to the start of second maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy the United States (US) IBM MarketScan database was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - UK</measure>
    <time_frame>At index date of the second maintenance treatment</time_frame>
    <description>Number of participants with zero exacerbations in the year prior to the start of second maintenance therapy among chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days Between Index and Initiation of First Maintenance Therapy - US</measure>
    <time_frame>From index date until initiation of first maintenance, up to 3368 days before this study started.</time_frame>
    <description>Days between index and initiation of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy the United States (US) IBM MarketScan database was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days Between Index and Initiation of First Maintenance Therapy - UK</measure>
    <time_frame>From index date until initiation of first maintenance therapy, up to 9795 days before this study started.</time_frame>
    <description>Days between index and initiation of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days Between First and Second Maintenance Therapy - US</measure>
    <time_frame>From the index date of first maintenance initiation until the initiation of the second maintenance therapy, up to 1020 days before this study started.</time_frame>
    <description>Days between first and second maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy the United States (US) IBM MarketScan database were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days Between First and Second Maintenance Therapy - UK</measure>
    <time_frame>From the index date of first maintenance initiation until the initiation of the second maintenance therapy, up to 10133 days before this study started.</time_frame>
    <description>Days between first and second maintenance therapy among chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1371146</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>COPD patients from US IBM Marketscan database</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD patients from UK CPRD GOLD database</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium bromide + Olodaterol</intervention_name>
    <description>Tiotropium bromide + Olodaterol</description>
    <arm_group_label>COPD patients from UK CPRD GOLD database</arm_group_label>
    <arm_group_label>COPD patients from US IBM Marketscan database</arm_group_label>
    <other_name>Sp(t)iolto® Respimat®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sp(t)iolto® Respimat®</intervention_name>
    <description>Sp(t)iolto® Respimat®</description>
    <arm_group_label>COPD patients from UK CPRD GOLD database</arm_group_label>
    <arm_group_label>COPD patients from US IBM Marketscan database</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population for the analysis will consist of all patients with at least one&#xD;
        medical claim with a diagnosis code of COPD identified.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  parent cohort&#xD;
&#xD;
             -- COPD diagnosis&#xD;
&#xD;
          -  child cohort&#xD;
&#xD;
             -- any initiation of first maintenance therapy after July 1, 2015&#xD;
&#xD;
          -  grandchild cohort -- any initiation of second maintenance therapy after August 2, 2015&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - parent cohort&#xD;
&#xD;
          -  age &lt;40 on index date&#xD;
&#xD;
          -  any COPD diagnosis in baseline&#xD;
&#xD;
          -  any use of long-acting muscarinic antagonists (LAMA), long-acting beta-agonists&#xD;
             (LABA), or inhaled corticosteroid (ICS) in baseline&#xD;
&#xD;
          -  &lt;365 days of continuous medical and pharmacy coverage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AETION inc</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 13, 2021</study_first_submitted>
  <study_first_submitted_qc>June 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2021</study_first_posted>
  <results_first_submitted>June 29, 2021</results_first_submitted>
  <results_first_submitted_qc>June 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 20, 2021</results_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
studies in products where Boehringer Ingelheim is not the license holder;&#xD;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;&#xD;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT04926233/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This retrospective cohort study used previously collected administrative healthcare data (United States data from IBM MarketScan and United Kingdom data from CPRD GOLD, a primary care database) to describe the patients characteristics and treatment patterns in patients with chronic obstructive pulmonary disease (COPD), initiating tiotropium + olodaterol or other maintenance therapies.</recruitment_details>
      <pre_assignment_details>Patients with chronic obstructive pulmonary disease (COPD) who met all inclusion criteria and none of the exclusion criteria initiating tiotropium + olodaterol or other maintenance therapies from either IBM MarketScan (United States) or CPRD GOLD (United Kingdom) databases were included.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>US IBM Marketscan - Overall</title>
          <description>All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).</description>
        </group>
        <group group_id="P2">
          <title>UK CPRD GOLD - Overall</title>
          <description>All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1280486"/>
                <participants group_id="P2" count="90660"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1280486"/>
                <participants group_id="P2" count="90660"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan (contained data collected from January 1, 2008 to March 31, 2018) and the United Kingdom (UK) CPRD GOLD databases (contained data collected from November 21, 1987 to June 30, 2018).</population>
      <group_list>
        <group group_id="B1">
          <title>US IBM Marketscan - Overall</title>
          <description>All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).</description>
        </group>
        <group group_id="B2">
          <title>UK CPRD GOLD - Overall</title>
          <description>All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1280486"/>
            <count group_id="B2" value="90660"/>
            <count group_id="B3" value="1371146"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1280486"/>
                    <count group_id="B2" value="90660"/>
                    <count group_id="B3" value="1371146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.3" spread="13.2"/>
                    <measurement group_id="B2" value="65.9" spread="13.5"/>
                    <measurement group_id="B3" value="65.3" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1280486"/>
                    <count group_id="B2" value="90660"/>
                    <count group_id="B3" value="1371146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="649296"/>
                    <measurement group_id="B2" value="46923"/>
                    <measurement group_id="B3" value="696219"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="631190"/>
                    <measurement group_id="B2" value="43737"/>
                    <measurement group_id="B3" value="674927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - US</title>
        <description>Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the United States (US) IBM MarketScan was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015).</description>
        <time_frame>At index date of cohort entry (baseline; time of COPD diagnosis).</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).</population>
        <group_list>
          <group group_id="O1">
            <title>US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval</title>
            <description>Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).&#xD;
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.</description>
          </group>
          <group group_id="O2">
            <title>US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval</title>
            <description>Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).&#xD;
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - US</title>
          <description>Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the United States (US) IBM MarketScan was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015).</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1021963"/>
                <count group_id="O2" value="258523"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6" spread="13.3"/>
                    <measurement group_id="O2" value="64.4" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - UK</title>
        <description>Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the the United Kingdom (UK) CPRD GOLD database was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015).</description>
        <time_frame>At index date of cohort entry (baseline; time of COPD diagnosis).</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).</population>
        <group_list>
          <group group_id="O1">
            <title>UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval</title>
            <description>Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).&#xD;
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.</description>
          </group>
          <group group_id="O2">
            <title>UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval</title>
            <description>Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).&#xD;
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - UK</title>
          <description>Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the the United Kingdom (UK) CPRD GOLD database was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015).</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79412"/>
                <count group_id="O2" value="11248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.82" spread="13.81"/>
                    <measurement group_id="O2" value="66.17" spread="11.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Charlson Comorbidity Index (CCI) at the Time of COPD Diagnosis</title>
        <description>The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was.</description>
        <time_frame>At index date of cohort entry (baseline; time of COPD diagnosis).</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan (contained data collected from January 1, 2008 to March 31, 2018) and the United Kingdom (UK) CPRD GOLD databases (contained data collected from November 21, 1987 to June 30, 2018). Results were reported by overall and by stratified groups according to Tiotropium + Olodaterol approval date for US and UK datasets, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>US IBM Marketscan - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).</description>
          </group>
          <group group_id="O2">
            <title>US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval</title>
            <description>Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).&#xD;
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval</title>
            <description>Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).&#xD;
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>UK CPRD GOLD - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).</description>
          </group>
          <group group_id="O5">
            <title>UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval</title>
            <description>Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).&#xD;
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval</title>
            <description>Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).&#xD;
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Charlson Comorbidity Index (CCI) at the Time of COPD Diagnosis</title>
          <description>The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan (contained data collected from January 1, 2008 to March 31, 2018) and the United Kingdom (UK) CPRD GOLD databases (contained data collected from November 21, 1987 to June 30, 2018). Results were reported by overall and by stratified groups according to Tiotropium + Olodaterol approval date for US and UK datasets, respectively.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280486"/>
                <count group_id="O2" value="1021963"/>
                <count group_id="O3" value="258523"/>
                <count group_id="O4" value="90660"/>
                <count group_id="O5" value="79412"/>
                <count group_id="O6" value="11248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.9"/>
                    <measurement group_id="O2" value="1.5" spread="1.9"/>
                    <measurement group_id="O3" value="1.9" spread="2.1"/>
                    <measurement group_id="O4" value="1.89" spread="1.38"/>
                    <measurement group_id="O5" value="1.83" spread="1.32"/>
                    <measurement group_id="O6" value="2.31" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Age of Patients Receiving First Maintenance Treatment - US</title>
        <description>Age of chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United States (US) IBM MarketScan database was reported.</description>
        <time_frame>At index date of the first maintenance treatment</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.</population>
        <group_list>
          <group group_id="O1">
            <title>US IBM Marketscan - 1MT - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.</description>
          </group>
          <group group_id="O2">
            <title>US IBM Marketscan - 1MT - ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Inhaled Corticosteroid (ICS) were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>US IBM Marketscan - 1MT - LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>US IBM Marketscan - 1MT - LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O5">
            <title>US IBM Marketscan - 1MT - LAMA+LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>US IBM Marketscan - 1MT - LAMA+LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O7">
            <title>US IBM Marketscan - 1MT - LAMA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.</description>
          </group>
          <group group_id="O8">
            <title>US IBM Marketscan - 1MT - LAMA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group</description>
          </group>
        </group_list>
        <measure>
          <title>Age of Patients Receiving First Maintenance Treatment - US</title>
          <description>Age of chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United States (US) IBM MarketScan database was reported.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53473"/>
                <count group_id="O2" value="6737"/>
                <count group_id="O3" value="351"/>
                <count group_id="O4" value="26378"/>
                <count group_id="O5" value="6745"/>
                <count group_id="O6" value="2237"/>
                <count group_id="O7" value="10892"/>
                <count group_id="O8" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" lower_limit="57.0" upper_limit="73.0"/>
                    <measurement group_id="O2" value="62.0" lower_limit="56.0" upper_limit="73.0"/>
                    <measurement group_id="O3" value="67.0" lower_limit="59.0" upper_limit="79.0"/>
                    <measurement group_id="O4" value="62.0" lower_limit="56.0" upper_limit="72.0"/>
                    <measurement group_id="O5" value="62.0" lower_limit="56.0" upper_limit="72.0"/>
                    <measurement group_id="O6" value="63.0" lower_limit="58.0" upper_limit="74.0"/>
                    <measurement group_id="O7" value="64.0" lower_limit="58.0" upper_limit="75.0"/>
                    <measurement group_id="O8" value="65.0" lower_limit="58.0" upper_limit="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Charlson Comorbidity Index (CCI) of Patients Receiving First Maintenance Treatment - US</title>
        <description>The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was.</description>
        <time_frame>At index date of the first maintenance treatment</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.</population>
        <group_list>
          <group group_id="O1">
            <title>US IBM Marketscan - 1MT - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.</description>
          </group>
          <group group_id="O2">
            <title>US IBM Marketscan - 1MT - ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Inhaled Corticosteroid (ICS) were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>US IBM Marketscan - 1MT - LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>US IBM Marketscan - 1MT - LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O5">
            <title>US IBM Marketscan - 1MT - LAMA+LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>US IBM Marketscan - 1MT - LAMA+LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O7">
            <title>US IBM Marketscan - 1MT - LAMA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.</description>
          </group>
          <group group_id="O8">
            <title>US IBM Marketscan - 1MT - LAMA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group</description>
          </group>
        </group_list>
        <measure>
          <title>Charlson Comorbidity Index (CCI) of Patients Receiving First Maintenance Treatment - US</title>
          <description>The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53473"/>
                <count group_id="O2" value="6737"/>
                <count group_id="O3" value="351"/>
                <count group_id="O4" value="26378"/>
                <count group_id="O5" value="6745"/>
                <count group_id="O6" value="2237"/>
                <count group_id="O7" value="10892"/>
                <count group_id="O8" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O7" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O8" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Characteristics of Patients Receiving First Maintenance Treatment - US</title>
        <description>Characteristics of patients receiving first maintenance treatment among chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United States (US) IBM MarketScan database were reported.</description>
        <time_frame>At index date of the first maintenance treatment</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.</population>
        <group_list>
          <group group_id="O1">
            <title>US IBM Marketscan - 1MT - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.</description>
          </group>
          <group group_id="O2">
            <title>US IBM Marketscan - 1MT - ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Inhaled Corticosteroid (ICS) were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>US IBM Marketscan - 1MT - LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>US IBM Marketscan - 1MT - LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O5">
            <title>US IBM Marketscan - 1MT - LAMA+LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>US IBM Marketscan - 1MT - LAMA+LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O7">
            <title>US IBM Marketscan - 1MT - LAMA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.</description>
          </group>
          <group group_id="O8">
            <title>US IBM Marketscan - 1MT - LAMA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Characteristics of Patients Receiving First Maintenance Treatment - US</title>
          <description>Characteristics of patients receiving first maintenance treatment among chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United States (US) IBM MarketScan database were reported.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53473"/>
                <count group_id="O2" value="6737"/>
                <count group_id="O3" value="351"/>
                <count group_id="O4" value="26378"/>
                <count group_id="O5" value="6745"/>
                <count group_id="O6" value="2237"/>
                <count group_id="O7" value="10892"/>
                <count group_id="O8" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Upper respiratory tract infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13803"/>
                    <measurement group_id="O2" value="2114"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="7151"/>
                    <measurement group_id="O5" value="1632"/>
                    <measurement group_id="O6" value="486"/>
                    <measurement group_id="O7" value="2299"/>
                    <measurement group_id="O8" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower respiratory tract infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8525"/>
                    <measurement group_id="O2" value="1160"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="4577"/>
                    <measurement group_id="O5" value="885"/>
                    <measurement group_id="O6" value="367"/>
                    <measurement group_id="O7" value="1474"/>
                    <measurement group_id="O8" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9946"/>
                    <measurement group_id="O2" value="1253"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="4762"/>
                    <measurement group_id="O5" value="1014"/>
                    <measurement group_id="O6" value="651"/>
                    <measurement group_id="O7" value="2160"/>
                    <measurement group_id="O8" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic bronchitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5161"/>
                    <measurement group_id="O2" value="603"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="2642"/>
                    <measurement group_id="O5" value="502"/>
                    <measurement group_id="O6" value="294"/>
                    <measurement group_id="O7" value="1066"/>
                    <measurement group_id="O8" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung fibrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1868"/>
                    <measurement group_id="O2" value="239"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="882"/>
                    <measurement group_id="O5" value="207"/>
                    <measurement group_id="O6" value="108"/>
                    <measurement group_id="O7" value="405"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concomitant medications - Oral corticosteroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23272"/>
                    <measurement group_id="O2" value="3172"/>
                    <measurement group_id="O3" value="152"/>
                    <measurement group_id="O4" value="12240"/>
                    <measurement group_id="O5" value="2770"/>
                    <measurement group_id="O6" value="929"/>
                    <measurement group_id="O7" value="3959"/>
                    <measurement group_id="O8" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concomitant medications - Oral antibiotics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37829"/>
                    <measurement group_id="O2" value="5047"/>
                    <measurement group_id="O3" value="249"/>
                    <measurement group_id="O4" value="19168"/>
                    <measurement group_id="O5" value="4645"/>
                    <measurement group_id="O6" value="1508"/>
                    <measurement group_id="O7" value="7116"/>
                    <measurement group_id="O8" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concomitant medications - Oxygen therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4580"/>
                    <measurement group_id="O2" value="425"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="2094"/>
                    <measurement group_id="O5" value="625"/>
                    <measurement group_id="O6" value="305"/>
                    <measurement group_id="O7" value="1058"/>
                    <measurement group_id="O8" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Age of Patients Receiving First Maintenance Treatment - UK</title>
        <description>Age of patients receiving first maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.</description>
        <time_frame>At index date of the first maintenance treatment</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.</population>
        <group_list>
          <group group_id="O1">
            <title>UK CPRD GOLD - 1MT - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.</description>
          </group>
          <group group_id="O2">
            <title>UK CPRD GOLD - 1MT - ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Inhaled Corticosteroid (ICS) were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>UK CPRD GOLD - 1MT - LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>UK CPRD GOLD - 1MT - LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O5">
            <title>UK CPRD GOLD - 1MT - LAMA+LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>UK CPRD GOLD - 1MT - LAMA+LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O7">
            <title>UK CPRD GOLD - 1MT - LAMA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.</description>
          </group>
          <group group_id="O8">
            <title>UK CPRD GOLD - 1MT - LAMA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Age of Patients Receiving First Maintenance Treatment - UK</title>
          <description>Age of patients receiving first maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.</population>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8786"/>
                <count group_id="O2" value="753"/>
                <count group_id="O3" value="382"/>
                <count group_id="O4" value="1202"/>
                <count group_id="O5" value="1407"/>
                <count group_id="O6" value="352"/>
                <count group_id="O7" value="4675"/>
                <count group_id="O8" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" lower_limit="60.0" upper_limit="75.0"/>
                    <measurement group_id="O2" value="67.0" lower_limit="59.0" upper_limit="75.0"/>
                    <measurement group_id="O3" value="67.0" lower_limit="59.0" upper_limit="75.0"/>
                    <measurement group_id="O4" value="67.0" lower_limit="59.0" upper_limit="75.0"/>
                    <measurement group_id="O5" value="68.0" lower_limit="61.0" upper_limit="75.0"/>
                    <measurement group_id="O6" value="70.0" lower_limit="62.0" upper_limit="77.0"/>
                    <measurement group_id="O7" value="68.0" lower_limit="60.0" upper_limit="75.0"/>
                    <measurement group_id="O8" value="69.0" lower_limit="64.0" upper_limit="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Characteristics of Patients Receiving First Maintenance Treatment - UK</title>
        <description>Characteristics of patients receiving first maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.</description>
        <time_frame>At index date of the first maintenance treatment</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.</population>
        <group_list>
          <group group_id="O1">
            <title>UK CPRD GOLD - 1MT - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.</description>
          </group>
          <group group_id="O2">
            <title>UK CPRD GOLD - 1MT - ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Inhaled Corticosteroid (ICS) were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>UK CPRD GOLD - 1MT - LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>UK CPRD GOLD - 1MT - LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O5">
            <title>UK CPRD GOLD - 1MT - LAMA+LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>UK CPRD GOLD - 1MT - LAMA+LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O7">
            <title>UK CPRD GOLD - 1MT - LAMA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.</description>
          </group>
          <group group_id="O8">
            <title>UK CPRD GOLD - 1MT - LAMA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Characteristics of Patients Receiving First Maintenance Treatment - UK</title>
          <description>Characteristics of patients receiving first maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8786"/>
                <count group_id="O2" value="753"/>
                <count group_id="O3" value="382"/>
                <count group_id="O4" value="1202"/>
                <count group_id="O5" value="1407"/>
                <count group_id="O6" value="352"/>
                <count group_id="O7" value="4675"/>
                <count group_id="O8" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Upper respiratory tract infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3802"/>
                    <measurement group_id="O2" value="454"/>
                    <measurement group_id="O3" value="166"/>
                    <measurement group_id="O4" value="545"/>
                    <measurement group_id="O5" value="541"/>
                    <measurement group_id="O6" value="143"/>
                    <measurement group_id="O7" value="1946"/>
                    <measurement group_id="O8" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower respiratory tract infection (not pneumonia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4835"/>
                    <measurement group_id="O2" value="501"/>
                    <measurement group_id="O3" value="220"/>
                    <measurement group_id="O4" value="721"/>
                    <measurement group_id="O5" value="732"/>
                    <measurement group_id="O6" value="164"/>
                    <measurement group_id="O7" value="2486"/>
                    <measurement group_id="O8" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concomitant medications - Oral corticosteroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2367"/>
                    <measurement group_id="O2" value="207"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="453"/>
                    <measurement group_id="O5" value="353"/>
                    <measurement group_id="O6" value="121"/>
                    <measurement group_id="O7" value="1140"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concomitant medications - Oral antibiotics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5133"/>
                    <measurement group_id="O2" value="480"/>
                    <measurement group_id="O3" value="204"/>
                    <measurement group_id="O4" value="796"/>
                    <measurement group_id="O5" value="797"/>
                    <measurement group_id="O6" value="224"/>
                    <measurement group_id="O7" value="2624"/>
                    <measurement group_id="O8" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Age of Patients Receiving Second Maintenance Treatment - US</title>
        <description>Age of patients receiving second maintenance treatment from the United States (US) IBM MarketScan database was reported.</description>
        <time_frame>At index date of the second maintenance treatment</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.</population>
        <group_list>
          <group group_id="O1">
            <title>US IBM Marketscan - 2MT - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>US IBM Marketscan - 2MT - ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Inhaled Corticosteroid (ICS) were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>US IBM Marketscan - 2MT - LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>US IBM Marketscan - 2MT - LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O5">
            <title>US IBM Marketscan - 2MT - LAMA+LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists(LAMA+LABA) were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>US IBM Marketscan - 2MT - LAMA+LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O7">
            <title>US IBM Marketscan - 2MT - LAMA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.</description>
          </group>
          <group group_id="O8">
            <title>US IBM Marketscan - 2MT - LAMA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Age of Patients Receiving Second Maintenance Treatment - US</title>
          <description>Age of patients receiving second maintenance treatment from the United States (US) IBM MarketScan database was reported.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.</population>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7028"/>
                <count group_id="O2" value="584"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="1813"/>
                <count group_id="O5" value="1125"/>
                <count group_id="O6" value="1834"/>
                <count group_id="O7" value="1450"/>
                <count group_id="O8" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" lower_limit="58.0" upper_limit="74.0"/>
                    <measurement group_id="O2" value="63.0" lower_limit="57.0" upper_limit="74.0"/>
                    <measurement group_id="O3" value="70.0" lower_limit="62.0" upper_limit="79.0"/>
                    <measurement group_id="O4" value="63.0" lower_limit="58.0" upper_limit="73.0"/>
                    <measurement group_id="O5" value="63.0" lower_limit="58.0" upper_limit="73.0"/>
                    <measurement group_id="O6" value="64.0" lower_limit="58.0" upper_limit="73.0"/>
                    <measurement group_id="O7" value="64.0" lower_limit="59.0" upper_limit="75.0"/>
                    <measurement group_id="O8" value="65.0" lower_limit="60.0" upper_limit="78.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Charlson Comorbidity Index (CCI) of Patients Receiving Second Maintenance Treatment - US</title>
        <description>The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was.</description>
        <time_frame>At index date of the second maintenance treatment</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.</population>
        <group_list>
          <group group_id="O1">
            <title>US IBM Marketscan - 2MT - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>US IBM Marketscan - 2MT - ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Inhaled Corticosteroid (ICS) were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>US IBM Marketscan - 2MT - LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>US IBM Marketscan - 2MT - LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O5">
            <title>US IBM Marketscan - 2MT - LAMA+LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists(LAMA+LABA) were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>US IBM Marketscan - 2MT - LAMA+LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O7">
            <title>US IBM Marketscan - 2MT - LAMA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.</description>
          </group>
          <group group_id="O8">
            <title>US IBM Marketscan - 2MT - LAMA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Charlson Comorbidity Index (CCI) of Patients Receiving Second Maintenance Treatment - US</title>
          <description>The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.</population>
          <units>Score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7028"/>
                <count group_id="O2" value="584"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="1813"/>
                <count group_id="O5" value="1125"/>
                <count group_id="O6" value="1834"/>
                <count group_id="O7" value="1450"/>
                <count group_id="O8" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O7" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O8" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Characteristics of Patients Receiving Second Maintenance Treatment - US</title>
        <description>Characteristics of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United States (US) IBM MarketScan database were reported.</description>
        <time_frame>At index date of the second maintenance treatment</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.</population>
        <group_list>
          <group group_id="O1">
            <title>US IBM Marketscan - 2MT - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>US IBM Marketscan - 2MT - ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Inhaled Corticosteroid (ICS) were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>US IBM Marketscan - 2MT - LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>US IBM Marketscan - 2MT - LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O5">
            <title>US IBM Marketscan - 2MT - LAMA+LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists(LAMA+LABA) were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>US IBM Marketscan - 2MT - LAMA+LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O7">
            <title>US IBM Marketscan - 2MT - LAMA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.</description>
          </group>
          <group group_id="O8">
            <title>US IBM Marketscan - 2MT - LAMA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Characteristics of Patients Receiving Second Maintenance Treatment - US</title>
          <description>Characteristics of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United States (US) IBM MarketScan database were reported.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7028"/>
                <count group_id="O2" value="584"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="1813"/>
                <count group_id="O5" value="1125"/>
                <count group_id="O6" value="1834"/>
                <count group_id="O7" value="1450"/>
                <count group_id="O8" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3674"/>
                    <measurement group_id="O2" value="265"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="920"/>
                    <measurement group_id="O5" value="628"/>
                    <measurement group_id="O6" value="998"/>
                    <measurement group_id="O7" value="749"/>
                    <measurement group_id="O8" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper respiratory tract infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1842"/>
                    <measurement group_id="O2" value="196"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="497"/>
                    <measurement group_id="O5" value="307"/>
                    <measurement group_id="O6" value="442"/>
                    <measurement group_id="O7" value="343"/>
                    <measurement group_id="O8" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower respiratory infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1385"/>
                    <measurement group_id="O2" value="130"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="368"/>
                    <measurement group_id="O5" value="213"/>
                    <measurement group_id="O6" value="372"/>
                    <measurement group_id="O7" value="260"/>
                    <measurement group_id="O8" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic bronchitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1095"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="264"/>
                    <measurement group_id="O5" value="165"/>
                    <measurement group_id="O6" value="297"/>
                    <measurement group_id="O7" value="243"/>
                    <measurement group_id="O8" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung fibrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="388"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="101"/>
                    <measurement group_id="O5" value="43"/>
                    <measurement group_id="O6" value="105"/>
                    <measurement group_id="O7" value="79"/>
                    <measurement group_id="O8" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concomitant medications - Oral corticosteroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4065"/>
                    <measurement group_id="O2" value="355"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="1019"/>
                    <measurement group_id="O5" value="595"/>
                    <measurement group_id="O6" value="1125"/>
                    <measurement group_id="O7" value="851"/>
                    <measurement group_id="O8" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concomitant medications - Oral antibiotics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5399"/>
                    <measurement group_id="O2" value="481"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="1399"/>
                    <measurement group_id="O5" value="833"/>
                    <measurement group_id="O6" value="1388"/>
                    <measurement group_id="O7" value="1126"/>
                    <measurement group_id="O8" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Age of Patients Receiving Second Maintenance Treatment - UK</title>
        <description>Age of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.</description>
        <time_frame>At index date of the second maintenance treatment</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.</population>
        <group_list>
          <group group_id="O1">
            <title>UK CPRD GOLD - 2MT - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>UK CPRD GOLD - 2MT - ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Inhaled Corticosteroid (ICS) were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>UK CPRD GOLD - 2MT - LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>UK CPRD GOLD - 2MT - LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O5">
            <title>UK CPRD GOLD - 2MT - LAMA+LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>UK CPRD GOLD - 2MT - LAMA+LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O7">
            <title>UK CPRD GOLD - 2MT - LAMA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.</description>
          </group>
          <group group_id="O8">
            <title>UK CPRD GOLD - 2MT - LAMA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Age of Patients Receiving Second Maintenance Treatment - UK</title>
          <description>Age of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.</population>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2461"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="338"/>
                <count group_id="O5" value="970"/>
                <count group_id="O6" value="685"/>
                <count group_id="O7" value="222"/>
                <count group_id="O8" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" lower_limit="61.0" upper_limit="75.0"/>
                    <measurement group_id="O2" value="68.0" lower_limit="61.5" upper_limit="74.0"/>
                    <measurement group_id="O3" value="71.0" lower_limit="63.0" upper_limit="76.0"/>
                    <measurement group_id="O4" value="69.0" lower_limit="61.0" upper_limit="77.0"/>
                    <measurement group_id="O5" value="68.0" lower_limit="61.0" upper_limit="74.0"/>
                    <measurement group_id="O6" value="68.0" lower_limit="60.0" upper_limit="74.0"/>
                    <measurement group_id="O7" value="70.0" lower_limit="62.0" upper_limit="77.0"/>
                    <measurement group_id="O8" value="68.0" lower_limit="59.0" upper_limit="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Characteristics of Patients Receiving Second Maintenance Treatment - UK</title>
        <description>Characteristics of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.</description>
        <time_frame>At index date of the second maintenance treatment</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.</population>
        <group_list>
          <group group_id="O1">
            <title>UK CPRD GOLD - 2MT - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>UK CPRD GOLD - 2MT - ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Inhaled Corticosteroid (ICS) were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>UK CPRD GOLD - 2MT - LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>UK CPRD GOLD - 2MT - LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O5">
            <title>UK CPRD GOLD - 2MT - LAMA+LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>UK CPRD GOLD - 2MT - LAMA+LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O7">
            <title>UK CPRD GOLD - 2MT - LAMA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.</description>
          </group>
          <group group_id="O8">
            <title>UK CPRD GOLD - 2MT - LAMA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Characteristics of Patients Receiving Second Maintenance Treatment - UK</title>
          <description>Characteristics of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2461"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="338"/>
                <count group_id="O5" value="970"/>
                <count group_id="O6" value="685"/>
                <count group_id="O7" value="222"/>
                <count group_id="O8" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1375"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="191"/>
                    <measurement group_id="O5" value="555"/>
                    <measurement group_id="O6" value="383"/>
                    <measurement group_id="O7" value="127"/>
                    <measurement group_id="O8" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concomitant medications - Oral corticosteroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1066"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="152"/>
                    <measurement group_id="O5" value="356"/>
                    <measurement group_id="O6" value="385"/>
                    <measurement group_id="O7" value="71"/>
                    <measurement group_id="O8" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - US</title>
        <description>Number of participants with zero exacerbations in the year prior to the start of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy the United States (US) IBM MarketScan database was reported.</description>
        <time_frame>At index date of the first maintenance treatment</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.</population>
        <group_list>
          <group group_id="O1">
            <title>US IBM Marketscan - 1MT - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.</description>
          </group>
          <group group_id="O2">
            <title>US IBM Marketscan - 1MT - ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Inhaled Corticosteroid (ICS) were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>US IBM Marketscan - 1MT - LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>US IBM Marketscan - 1MT - LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O5">
            <title>US IBM Marketscan - 1MT - LAMA+LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>US IBM Marketscan - 1MT - LAMA+LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O7">
            <title>US IBM Marketscan - 1MT - LAMA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.</description>
          </group>
          <group group_id="O8">
            <title>US IBM Marketscan - 1MT - LAMA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - US</title>
          <description>Number of participants with zero exacerbations in the year prior to the start of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy the United States (US) IBM MarketScan database was reported.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53473"/>
                <count group_id="O2" value="6737"/>
                <count group_id="O3" value="351"/>
                <count group_id="O4" value="26378"/>
                <count group_id="O5" value="6745"/>
                <count group_id="O6" value="2237"/>
                <count group_id="O7" value="10892"/>
                <count group_id="O8" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26242"/>
                    <measurement group_id="O2" value="3518"/>
                    <measurement group_id="O3" value="183"/>
                    <measurement group_id="O4" value="12483"/>
                    <measurement group_id="O5" value="3818"/>
                    <measurement group_id="O6" value="676"/>
                    <measurement group_id="O7" value="5515"/>
                    <measurement group_id="O8" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - UK</title>
        <description>Number of participants with zero exacerbations in the year prior to the start of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.</description>
        <time_frame>At index date of the first maintenance treatment</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.</population>
        <group_list>
          <group group_id="O1">
            <title>UK CPRD GOLD - 1MT - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.</description>
          </group>
          <group group_id="O2">
            <title>UK CPRD GOLD - 1MT - ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Inhaled Corticosteroid (ICS) were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>UK CPRD GOLD - 1MT - LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>UK CPRD GOLD - 1MT - LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O5">
            <title>UK CPRD GOLD - 1MT - LAMA+LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>UK CPRD GOLD - 1MT - LAMA+LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O7">
            <title>UK CPRD GOLD - 1MT - LAMA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.</description>
          </group>
          <group group_id="O8">
            <title>UK CPRD GOLD - 1MT - LAMA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - UK</title>
          <description>Number of participants with zero exacerbations in the year prior to the start of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8786"/>
                <count group_id="O2" value="753"/>
                <count group_id="O3" value="382"/>
                <count group_id="O4" value="1202"/>
                <count group_id="O5" value="1407"/>
                <count group_id="O6" value="352"/>
                <count group_id="O7" value="4675"/>
                <count group_id="O8" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5942"/>
                    <measurement group_id="O2" value="498"/>
                    <measurement group_id="O3" value="275"/>
                    <measurement group_id="O4" value="712"/>
                    <measurement group_id="O5" value="960"/>
                    <measurement group_id="O6" value="207"/>
                    <measurement group_id="O7" value="3281"/>
                    <measurement group_id="O8" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - US</title>
        <description>Number of participants with zero exacerbations in the year prior to the start of second maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy the United States (US) IBM MarketScan database was reported.</description>
        <time_frame>At index date of the second maintenance treatment</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.</population>
        <group_list>
          <group group_id="O1">
            <title>US IBM Marketscan - 2MT - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>US IBM Marketscan - 2MT - ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Inhaled Corticosteroid (ICS) were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>US IBM Marketscan - 2MT - LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>US IBM Marketscan - 2MT - LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O5">
            <title>US IBM Marketscan - 2MT - LAMA+LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists(LAMA+LABA) were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>US IBM Marketscan - 2MT - LAMA+LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O7">
            <title>US IBM Marketscan - 2MT - LAMA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.</description>
          </group>
          <group group_id="O8">
            <title>US IBM Marketscan - 2MT - LAMA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - US</title>
          <description>Number of participants with zero exacerbations in the year prior to the start of second maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy the United States (US) IBM MarketScan database was reported.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7028"/>
                <count group_id="O2" value="584"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="1813"/>
                <count group_id="O5" value="1125"/>
                <count group_id="O6" value="1834"/>
                <count group_id="O7" value="1450"/>
                <count group_id="O8" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2361"/>
                    <measurement group_id="O2" value="226"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="684"/>
                    <measurement group_id="O5" value="426"/>
                    <measurement group_id="O6" value="505"/>
                    <measurement group_id="O7" value="451"/>
                    <measurement group_id="O8" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - UK</title>
        <description>Number of participants with zero exacerbations in the year prior to the start of second maintenance therapy among chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.</description>
        <time_frame>At index date of the second maintenance treatment</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.</population>
        <group_list>
          <group group_id="O1">
            <title>UK CPRD GOLD - 2MT - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>UK CPRD GOLD - 2MT - ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Inhaled Corticosteroid (ICS) were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>UK CPRD GOLD - 2MT - LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>UK CPRD GOLD - 2MT - LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O5">
            <title>UK CPRD GOLD - 2MT - LAMA+LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>UK CPRD GOLD - 2MT - LAMA+LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O7">
            <title>UK CPRD GOLD - 2MT - LAMA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.</description>
          </group>
          <group group_id="O8">
            <title>UK CPRD GOLD - 2MT - LAMA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - UK</title>
          <description>Number of participants with zero exacerbations in the year prior to the start of second maintenance therapy among chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2461"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="338"/>
                <count group_id="O5" value="970"/>
                <count group_id="O6" value="685"/>
                <count group_id="O7" value="222"/>
                <count group_id="O8" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1351"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="172"/>
                    <measurement group_id="O5" value="590"/>
                    <measurement group_id="O6" value="299"/>
                    <measurement group_id="O7" value="144"/>
                    <measurement group_id="O8" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Between Index and Initiation of First Maintenance Therapy - US</title>
        <description>Days between index and initiation of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy the United States (US) IBM MarketScan database was reported.</description>
        <time_frame>From index date until initiation of first maintenance, up to 3368 days before this study started.</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.</population>
        <group_list>
          <group group_id="O1">
            <title>US IBM Marketscan - 1MT - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.</description>
          </group>
          <group group_id="O2">
            <title>US IBM Marketscan - 1MT - ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Inhaled Corticosteroid (ICS) were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>US IBM Marketscan - 1MT - LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>US IBM Marketscan - 1MT - LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O5">
            <title>US IBM Marketscan - 1MT - LAMA+LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>US IBM Marketscan - 1MT - LAMA+LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O7">
            <title>US IBM Marketscan - 1MT - LAMA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.</description>
          </group>
          <group group_id="O8">
            <title>US IBM Marketscan - 1MT - LAMA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Days Between Index and Initiation of First Maintenance Therapy - US</title>
          <description>Days between index and initiation of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy the United States (US) IBM MarketScan database was reported.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53473"/>
                <count group_id="O2" value="6737"/>
                <count group_id="O3" value="351"/>
                <count group_id="O4" value="26378"/>
                <count group_id="O5" value="6745"/>
                <count group_id="O6" value="2237"/>
                <count group_id="O7" value="10892"/>
                <count group_id="O8" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.0" lower_limit="12.0" upper_limit="839.0"/>
                    <measurement group_id="O2" value="242.0" lower_limit="17.0" upper_limit="972.0"/>
                    <measurement group_id="O3" value="233.0" lower_limit="14.0" upper_limit="902.0"/>
                    <measurement group_id="O4" value="165.0" lower_limit="12.0" upper_limit="833.0"/>
                    <measurement group_id="O5" value="116.0" lower_limit="15.0" upper_limit="672.0"/>
                    <measurement group_id="O6" value="78.0" lower_limit="7.0" upper_limit="770.0"/>
                    <measurement group_id="O7" value="136.0" lower_limit="9.0" upper_limit="879.0"/>
                    <measurement group_id="O8" value="85.0" lower_limit="6.0" upper_limit="957.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Between Index and Initiation of First Maintenance Therapy - UK</title>
        <description>Days between index and initiation of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.</description>
        <time_frame>From index date until initiation of first maintenance therapy, up to 9795 days before this study started.</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.</population>
        <group_list>
          <group group_id="O1">
            <title>UK CPRD GOLD - 1MT - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.</description>
          </group>
          <group group_id="O2">
            <title>UK CPRD GOLD - 1MT - ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Inhaled Corticosteroid (ICS) were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>UK CPRD GOLD - 1MT - LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>UK CPRD GOLD - 1MT - LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O5">
            <title>UK CPRD GOLD - 1MT - LAMA+LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>UK CPRD GOLD - 1MT - LAMA+LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O7">
            <title>UK CPRD GOLD - 1MT - LAMA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.</description>
          </group>
          <group group_id="O8">
            <title>UK CPRD GOLD - 1MT - LAMA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Days Between Index and Initiation of First Maintenance Therapy - UK</title>
          <description>Days between index and initiation of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8786"/>
                <count group_id="O2" value="753"/>
                <count group_id="O3" value="382"/>
                <count group_id="O4" value="1202"/>
                <count group_id="O5" value="1407"/>
                <count group_id="O6" value="352"/>
                <count group_id="O7" value="4675"/>
                <count group_id="O8" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" lower_limit="1.0" upper_limit="521.0"/>
                    <measurement group_id="O2" value="708.0" lower_limit="43.0" upper_limit="3145.0"/>
                    <measurement group_id="O3" value="43.5" lower_limit="1.0" upper_limit="555.0"/>
                    <measurement group_id="O4" value="32.0" lower_limit="1.0" upper_limit="566.0"/>
                    <measurement group_id="O5" value="19.0" lower_limit="1.0" upper_limit="368.0"/>
                    <measurement group_id="O6" value="19.0" lower_limit="1.0" upper_limit="141.5"/>
                    <measurement group_id="O7" value="22.0" lower_limit="1.0" upper_limit="376.0"/>
                    <measurement group_id="O8" value="19.0" lower_limit="1.0" upper_limit="123.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Between First and Second Maintenance Therapy - US</title>
        <description>Days between first and second maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy the United States (US) IBM MarketScan database were reported.</description>
        <time_frame>From the index date of first maintenance initiation until the initiation of the second maintenance therapy, up to 1020 days before this study started.</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.</population>
        <group_list>
          <group group_id="O1">
            <title>US IBM Marketscan - 2MT - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>US IBM Marketscan - 2MT - ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Inhaled Corticosteroid (ICS) were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>US IBM Marketscan - 2MT - LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>US IBM Marketscan - 2MT - LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O5">
            <title>US IBM Marketscan - 2MT - LAMA+LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists(LAMA+LABA) were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>US IBM Marketscan - 2MT - LAMA+LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O7">
            <title>US IBM Marketscan - 2MT - LAMA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.</description>
          </group>
          <group group_id="O8">
            <title>US IBM Marketscan - 2MT - LAMA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Days Between First and Second Maintenance Therapy - US</title>
          <description>Days between first and second maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy the United States (US) IBM MarketScan database were reported.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7028"/>
                <count group_id="O2" value="584"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="1813"/>
                <count group_id="O5" value="1125"/>
                <count group_id="O6" value="1834"/>
                <count group_id="O7" value="1450"/>
                <count group_id="O8" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.0" lower_limit="76.0" upper_limit="335.0"/>
                    <measurement group_id="O2" value="181.5" lower_limit="89.5" upper_limit="339.5"/>
                    <measurement group_id="O3" value="176.0" lower_limit="86.0" upper_limit="282.0"/>
                    <measurement group_id="O4" value="158.0" lower_limit="74.0" upper_limit="321.0"/>
                    <measurement group_id="O5" value="223.0" lower_limit="100.0" upper_limit="415.0"/>
                    <measurement group_id="O6" value="143.5" lower_limit="70.0" upper_limit="314.0"/>
                    <measurement group_id="O7" value="137.0" lower_limit="66.0" upper_limit="301.0"/>
                    <measurement group_id="O8" value="125.0" lower_limit="67.0" upper_limit="266.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Between First and Second Maintenance Therapy - UK</title>
        <description>Days between first and second maintenance therapy among chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.</description>
        <time_frame>From the index date of first maintenance initiation until the initiation of the second maintenance therapy, up to 10133 days before this study started.</time_frame>
        <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.</population>
        <group_list>
          <group group_id="O1">
            <title>UK CPRD GOLD - 2MT - Overall</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>UK CPRD GOLD - 2MT - ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Inhaled Corticosteroid (ICS) were included in this group.</description>
          </group>
          <group group_id="O3">
            <title>UK CPRD GOLD - 2MT - LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group.</description>
          </group>
          <group group_id="O4">
            <title>UK CPRD GOLD - 2MT - LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O5">
            <title>UK CPRD GOLD - 2MT - LAMA+LABA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group.</description>
          </group>
          <group group_id="O6">
            <title>UK CPRD GOLD - 2MT - LAMA+LABA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group.</description>
          </group>
          <group group_id="O7">
            <title>UK CPRD GOLD - 2MT - LAMA</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.</description>
          </group>
          <group group_id="O8">
            <title>UK CPRD GOLD - 2MT - LAMA+ICS</title>
            <description>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.&#xD;
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Days Between First and Second Maintenance Therapy - UK</title>
          <description>Days between first and second maintenance therapy among chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.</description>
          <population>All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2461"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="338"/>
                <count group_id="O5" value="970"/>
                <count group_id="O6" value="685"/>
                <count group_id="O7" value="222"/>
                <count group_id="O8" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.0" lower_limit="86.0" upper_limit="428.0"/>
                    <measurement group_id="O2" value="239.5" lower_limit="61.5" upper_limit="528.0"/>
                    <measurement group_id="O3" value="141.0" lower_limit="74.0" upper_limit="412.0"/>
                    <measurement group_id="O4" value="155.5" lower_limit="67.0" upper_limit="335.0"/>
                    <measurement group_id="O5" value="284.0" lower_limit="113.0" upper_limit="483.0"/>
                    <measurement group_id="O6" value="197.0" lower_limit="82.0" upper_limit="397.0"/>
                    <measurement group_id="O7" value="225.5" lower_limit="96.0" upper_limit="415.0"/>
                    <measurement group_id="O8" value="158.0" lower_limit="71.0" upper_limit="281.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>This study was based on the use of secondary data without access to individual patient data. Adverse events were not collected. Zeros in the numbers of participants at risk and affected in the &quot;All-Cause Mortality&quot;, &quot;Serious Adverse Events&quot;, and &quot;Other Adverse Events&quot; sections stand for adverse event was not collected and not available for this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>US IBM Marketscan - Overall</title>
          <description>All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).</description>
        </group>
        <group group_id="E2">
          <title>UK CPRD GOLD - Overall</title>
          <description>All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.&#xD;
Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.&#xD;
BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

